Posted by Michael Wonder on 20 May 2021
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
14 May 2021 - The UK NICE has recommended Bristol Myers Squibb’s Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer .
Following the positive final appraisal document, Opdivo becomes the first immuno-oncology monotherapy for the treatment of oesophageal squamous cell cancer patients in England who have previously failed chemotherapy.
